Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2006-4-3
pubmed:abstractText
OBJECTIVES: The risk of venous thrombosis during cancer is largely increased especially in case of chemotherapy, surgery, advanced stage disease, coagulation abnormalities. Survival of patients with cancer experiencing venous thrombosis seems to be worse. Although thrombosis may be a presenting feature of occult malignancy, there are insufficient data to support a more extensive screening than comprehensive medical history, physical examination, routine laboratory tests and chest radiography. CURRENT KNOWLEDGE AND KEY POINTS: Pathophysiology of venous thrombosis during cancer is unspecific: venous stasis, vessel wall damage, hypercoagulability). Other factors like platelet abnormalities or the direct responsibility of chemotherapy or hormonotherapy have recently been though to play a causative role. Treatment of cancer-associated thrombosis usually requires at least 6 months of low-molecular-weight heparin therapy rather than oral anticoagulant. Inferior vena cava filters are not indicated. Primary prophylaxis of thrombosis during cancer could safely been achieved with low-molecular-weight heparin. Central venous catheters can be associated with thrombotic complications. Many risks factors have been identified: catheter's type, modalities of catheter's implantation, type of perfusion, bulky mediastinal mass... Prophylactic anticoagulation is not routinely recommended. FUTURE PROSPECTS AND PROJECTS: Knew oral anticoagulants could facilitate the treatment of venous thrombosis occurring during cancer in the next years.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0248-8663
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
313-22
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:16414153-Administration, Oral, pubmed-meshheading:16414153-Anticoagulants, pubmed-meshheading:16414153-Blood Coagulation, pubmed-meshheading:16414153-Blood Platelet Disorders, pubmed-meshheading:16414153-Catheterization, Central Venous, pubmed-meshheading:16414153-Female, pubmed-meshheading:16414153-Forecasting, pubmed-meshheading:16414153-Heparin, Low-Molecular-Weight, pubmed-meshheading:16414153-Humans, pubmed-meshheading:16414153-Incidence, pubmed-meshheading:16414153-Male, pubmed-meshheading:16414153-Middle Aged, pubmed-meshheading:16414153-Neoplasms, pubmed-meshheading:16414153-Postoperative Complications, pubmed-meshheading:16414153-Primary Prevention, pubmed-meshheading:16414153-Prognosis, pubmed-meshheading:16414153-Prospective Studies, pubmed-meshheading:16414153-Randomized Controlled Trials as Topic, pubmed-meshheading:16414153-Risk, pubmed-meshheading:16414153-Risk Factors, pubmed-meshheading:16414153-Thromboembolism, pubmed-meshheading:16414153-Time Factors, pubmed-meshheading:16414153-Venous Thrombosis
pubmed:year
2006
pubmed:articleTitle
[Venous thromboembolism and cancer].
pubmed:affiliation
Service de Médecine Interne, Hôpital d'Instruction des Armées Desgenettes, 108, boulevard Pinel, 69003 Lyon, France. m.pavic@chello.fr
pubmed:publicationType
Journal Article, Comparative Study, English Abstract, Review